Product Showcase – Novosprint High Speed Doors

Lateral Thinking for Superior Speed and Safety

Novosprint high speed doors are ideal for all industrial, supermarket and pharmaceutical environments. With its lateral opening technology, its opening speed of up to 5 m/s and its closing speed of up to 2.5 m/s, the NOVOSPRINT door is the most reliable solution for speed and safety in the workplace.

the novosprint principle


Faster Opening

Instead of the traditional vertical opening, the Novosprint door opens horizontally for twice the speed and significantly improved safety. The two halves of the door open sideways in less than a second. This makes the entire height of the door immediately accessible and drastically cuts the risk of collisions or accidents.

Increased Safety

An opening speed of up to 5 m/s and closing speed up to 2.5 m/s enables faster and safer transport of goods. This trouble-free flow of traffic and goods avoids collisions, long interruptions and costly door repairs. The transparent vision panels at eye-level also maintain visibility between one area and the next, even when the door is closed.

More Economical

Low purchase price, low operation costs and low maintenance costs. Short opening and closing cycles reduce draught and heat exchange, thus reducing energy costs and the possibility of illness.

Better Hygiene & Contamination Control

The Novosprint principle of side opening ensures that no dirt spreads from the ground onto workers or any goods being transported. That’s because unlike vertical doors, the door does not come into contact with the floor and pick up dust or dirt which is then left to drip or fall onto passing objects below. The Novosprint hygiene door is an alternative solution which has been developed to meet the requirements of the food and pharmaceutical industries. In compliance with regulations, all tangible parts of the door are made of non porous and corrosion resistant material, such as Stainless Steel and plastics.

Have a look at our product brochure or contact us for more information.

novosprint high speed doors dortek

China Stem Cell Clinical Applications Center – Hong Kong Science Park

Dortek have recently supplied ultra hygienic door systems to CRMI’s (China Regenerative Medicine International) China Applications Center in Hong Kong. The center is set to be a world-class GMP centre specializing in stem cell clinical applications and gene therapy, as well as a regional supply centre of cellular products for related research and medical institutions.

The centre in Hong Kong aims to bridge the long unresolved gap between basic research scientists and clinicians by providing various clinical-graded stem cells, including autologous stem cells, allogeneic stem cells, and genetically-modified stem cells. These stem cells are suitable for various clinical applications including immunotherapy, neural regeneration, cardiovascular regeneration, bone and connective tissue regeneration, ocular regeneration, and human organ regeneration.

The state-of-the-art facility complies with the highest standards set forth by the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and China Food and Drug Administration (CFDA).

Dortek supplied 20 single action GRP doors with an hour’s fire rating. Our void free doors are free from cracks and joints making them the most hygienic solution for research facilities. The moulded seamless construction of a Dortek door makes it easy to clean, non absorbent and able to withstand the intensive cleaning regimes used in healthcare research and production facilities.

About CRMI

China Regenerative Medicine International is a tissue engineering company. With only 5,000 corneas donated each year for transplants, millions of Chinese citizens who need a cornea transplant to regain their eyesight have been forced to wait–or give up hope. But since 2000, CRMI has been working on an artificial cornea that could be used instead of donated ones. It landed on an unprecedented idea–to use pigs’ corneas, rather than constructing wholly artificial ones–and in 2013 clinical trials; they produced stunning results, with more than 90% of patients responding well to the surgery.

In 2015, the China Food and Drug Administration approved the artificial corneas for widespread use, and CRMI began mass production. CRMI also announced a partnership with China Resources Healthcare Group to help the company bring its groundbreaking product to hospitals and providers. The partnership will also provide a platform to promote its other regenerative products, which focus on skin and cartilage.

Back To Top